TY  - JOUR
T1  - BEvacizumab and cancer treatment-related mortality—reply
AU  - Wu S, Ranpura V, Hapani S
Y1  - 2011/06/08
N1  - 10.1001/jama.2011.760
JO  - JAMA
SP  - 2291
EP  - 2293
VL  - 305
IS  - 22
N2  - 
The goal of our study was to provide insight into the risk of FAEs related to chemotherapy associated with a biological agent, in this case bevacizumab. These events are most likely the result of serious adverse effects from the treatment, as shown in our study. We agree with Dr Punt and colleagues that many FAEs could be prevented by better adherence to treatment guidelines and adequate patient care. However, our study, being a meta-analysis, was limited in assessing these issues. The included studies did not contain any information regarding the assessment of the relationship between FAEs and treatment and major protocol violations and monitoring results.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2011.760
UR  - http://dx.doi.org/10.1001/jama.2011.760
ER  -